Table 1.
Ob (n = 24) | Ob-NAFLD (n = 24) | p-Value | |
---|---|---|---|
Age (years) a | 44.88 ± 10.87 | 45.75 ± 8.94 | 0.762 |
BMI (kg/m2) a | 44.00 ± 5.32 | 44.41 ± 4.75 | 0.778 |
Waist (cm) | 118.5 (111.3–129.3) | 119.5 (116.3–125.8) | 0.900 |
Hip (cm) | 137.7 ± 9.49 | 133.2 ± 9.145 | 0.222 |
Waist-to-hip ratio | 0.88 ± 0.08 | 0.91 ± 0.05 | 0.246 |
CUN-BAE Index | 54.2 (52.3–55.6) | 54.5 (52.7–56.5) | 0.660 |
HTN | 5 (20.83%) | 9 (37.50%) | 0.341 b |
TG (mg/dL) | 189.0 ± 33.02 | 200.0 ± 37.96 | 0.027 |
Total cholesterol (mg/dL) | 193.82 ± 24.44 | 202.55 ± 36.2 | 0.289 |
HDL (mg/dL) | 53.75 ± 8.65 | 45.58 ± 7.88 | 0.001 |
LDL (mg/dL) | 116.3 ± 25.08 | 125.2 ± 29.96 | 0.277 |
FPG (mg/dL) | 90.5 (88.5–101.0) | 99.0 (90.5–105.8) | 0.264 |
T2D a | 5 (20.83%) | 5 (20.83%) | >0.999 b |
HbA1c (%) | 5.5 (5.3–5.7) | 5.6 (5.3–6.1) | 0.493 |
AST (IU/L) | 20.5 (16.7–23.0) | 21.0 (17.0–27.7) | 0.454 |
ALT (IU/L) | 21.0 (15.0–25.0) | 22.0 (17.2–40.5) | 0.159 |
GGT (IU/L) | 19.0 (14.0–31.0) | 24.0 (18.2–38.7) | 0.349 |
AST:ALT ratio | 1.0 (0.8–1.1) | 0.8 (0.6–1.0) | 0.158 |
Platelets (×109/L) | 268 (241–306) | 294 (248–382) | 0.125 |
CRP (mg/dL) | 0.48 (0.34–1.21) | 0.95 (0.38–1.81) | 0.230 |
FIB-4 Score | 0.71 (0.51–0.86) | 0.69 (0.44–0.91) | 0.778 |
APRI Score | 0.18 (0.14–0.22) | 0.19 (0.14–0.21) | 0.813 |
Data are presented mean ± SD, median (IQR) or n (%). NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; CUN-BAE Index, body adiposity estimator; HTN, hypertension; TG, serum triglyceride level; HDL, serum high-density lipoprotein cholesterol level; LDL, serum low density lipoprotein cholesterol level; FPG, fasting plasma glucose; T2D, type 2 diabetes; HbA1c, glycosylated haemoglobin; AST, serum aspartate aminotransferase level; ALT, serum alanine aminotransferase level; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; FIB-4, index for liver fibrosis; APRI, AST to platelet ratio index. Welch’s t-test or Mann-Whitney test were applied except otherwise stated. a Matching variable. b Fisher’s exact test.